In my opinion,  for what it's worth, a successful Zen trial resulting in FDA approval of a zen combo therapy will be the catalyst. Several BPs are currently involved with zen in developing these novel therapies. FDA approval derisks the concept, takes the product to market and opens up the floodgates.

Approval will spotlight Apabetalone, a breakthrough therapy drug with stellar secondary BOM trial results with a .0002 p value.  Having been derisked, Rvx will be a BP target for purchase or codevelopment in a BOM2 trial. At the very least, Zen approval and marketability will fund BOM2.

How much longer must we wait? We are almost there. We need FDA approval.

Chicagoest